Meningococcal Disease Vaccine Market Analysis and Size

Meningococcal disease is an uncommon infection caused by the bacteria Neisseria meningitidis that affects the lining of the brain, spinal cord, and blood. The germs that cause meningococcal disease transmit by saliva or spit, usually through direct contact with sick persons and subsequent contact.

Meningococcal septicemia occurs when the meningococcal infection spreads to the bloodstream, causing bleeding into the skin and organs, fever and chills, vomiting and diarrhoea, and chilly hands and feet. Headache, stiff neck, heightened sensitivity to light, and feeling disoriented are some of the other symptoms. Protection against these infections is extremely crucial because they can swiftly turn lethal, causing major disabilities such as hearing loss or brain damage, or even death in just a few hours.

Data Bridge Market Research analyses that the meningococcal disease vaccine market was valued at USD 3.08 billion in 2021 and is expected to reach USD 6.60 billion by 2029, registering a CAGR of 10.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and sub capsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.

Get PDF Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-meningococcal-disease-vaccine-market

Meningococcal Disease Vaccine Market Dynamics

Drivers

·       Increasing prevalence of meningitis

The rising prevalence of meningitis is estimated to enhance the meningococcal disease vaccine market's growth rate. Meningitis is an inflammation of the brain and spinal cord's inner lining caused by infectious (viral, bacterial, and occasionally fungal) or non-infectious sources. Meningitis is a deadly disease with a quick onset of symptoms. Meningitis can cause significant brain damage in about half of the afflicted population if left untreated. Mental retardation, epilepsy, and deafness are only a few of the significant side effects. According to the Meningitis Research Foundation, enteroviruses are responsible for approximately 80% to 90% of meningitis cases in 2017, with the remaining 10% being caused by herpes virus, mumps, measles, and human immunodeficiency virus.

·       Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of meningococcal disease vaccine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, increasing public-private partnerships to support the development of vaccines at low cost and rising level of disposable income will expand the meningococcal disease vaccine market. Additionally, the increasing prevalence of the meningococcal disease among young children and adolescents across the globe and increasing number of government initiatives to spread awareness are estimated to enhance the market’s growth rate.

Opportunities

·       Increase in the number of research and development activities   

The meningococcal disease vaccine market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the meningococcal disease vaccine market growth.

Meningococcal Disease Vaccine Market Regional Analysis/Insights

The meningococcal disease vaccine market is analyzed and market size insights and trends are provided by country, vaccine serotype, age group, vaccine type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the meningococcal disease vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the meningococcal disease vaccine market because of the presence of key manufacture of the product and rising healthcare expenditure in this region. Additionally, high research and development expenditure and reduced incidence rate of meningitis will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, the growing number of patient population will further cushion the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Get TOC Detail of Research Report @ https://www.databridgemarketresearch.com/toc/?dbmr=global-meningococcal-disease-vaccine-market

Global Meningococcal Disease Vaccine Market Scope

The meningococcal disease vaccine market is segmented on the basis of vaccine serotype, age group, vaccine type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Vaccine Serotype

·       MenACWY

·       MenB and Manic

·       MenC

·       MenA

·       MenAC

·       Others

Age Group

·       Infants (0 to 2 years)

·       Children and Adults (2 years and above)

Vaccine Type

·       Polysaccharide

·       Conjugate

·       Combination

Route of Administration

·       Parenteral

·       Others

End-Users

·       Hospitals

·       Specialty Clinics

·       Homecare

·       Others

Distribution Channel

·       Hospital Pharmacy

·       Retail Pharmacy

·       Online Pharmacy

·       Others

Competitive Landscape and Meningococcal Disease Vaccine Market Share Analysis

The meningococcal disease vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to meningococcal disease vaccine market.

Some of the major players operating in the meningococcal disease vaccine market are:

·       AstraZeneca (U.K.)

·       Johnson & Johnson Private Limited (U.S.)

·       Mylan N.V. (U.S.)

·       Teva Pharmaceutical Industries Ltd.(Israel)

·       Pfizer Inc. (U.S.)

·       GlaxoSmithKline plc (U.K.)

·       Novartis AG (Switzerland)

·       Sanofi (France)

·       Merck & Co., Inc. (U.S.)

·       F. Hoffmann-La Roche Ltd. (Switzerland)

·       Serum Institute of India Pvt. Ltd. (India)

·       Baxter (U.S.)

·       Walvax Biotechnology Co., Ltd. (China)

·       BIO-MED (India)

·       Bio-Manguinhos (Brazil)

Browse in-depth Research Report @ https://www.databridgemarketresearch.com/reports/global-meningococcal-disease-vaccine-market

Top Related Reports:-

https://www.databridgemarketresearch.com/reports/global-addisons-disease-drugs-market

https://www.databridgemarketresearch.com/reports/global-fibromyalgia-market

https://www.databridgemarketresearch.com/reports/global-fabry-disease-market

https://www.databridgemarketresearch.com/reports/global-eosinophil-driven-diseases-market

https://www.databridgemarketresearch.com/reports/global-renal-drugs-market

About us: -
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in pune.

Data bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and ha bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact us: -
Data bridge market research
Us: +1 888 387 2818
Email: - corporatesales@databridgemarketresearch.com